企業プロフィール
Keros Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- KROS
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
10.78 USD (-2.27%)
終値
最終更新: 2026年8月24日
209M USD
時価総額
株価変動の要因
As of Aug 24, 2026, KROS closed down 2.27% at $10.78. No new same-company headline was identified in the current news window.
企業概要
TGF-β Biology Platform
Keros Therapeutics develops protein therapeutics for diseases linked to dysfunctional signaling within the transforming growth factor-beta family, which regulates muscle, bone, adipose tissue, cardiac tissue, and blood-cell development.
Rinvatercept
Rinvatercept is the company’s lead internally controlled candidate and is being developed for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
Elritercept Partnership
Elritercept targets cytopenias, including anemia and thrombocytopenia, in myelodysplastic syndromes and myelofibrosis. Takeda has assumed development responsibility under a licensing partnership.
今後のカタリスト
- Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。